| Budget Amount *help |
¥44,850,000 (Direct Cost: ¥34,500,000、Indirect Cost: ¥10,350,000)
Fiscal Year 2020: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
Fiscal Year 2019: ¥12,870,000 (Direct Cost: ¥9,900,000、Indirect Cost: ¥2,970,000)
Fiscal Year 2018: ¥20,800,000 (Direct Cost: ¥16,000,000、Indirect Cost: ¥4,800,000)
|
|---|
| Outline of Final Research Achievements |
AFunctional analysis of variants of the type 2 diabetes susceptibility gene region was performed. It was shown that two different variants of the same gene region could regulate the expression of different genes in different tissues (Nature 2020). As a result of performing chromatin immunoprecipitation sequence and evaluating which transcription factor binding site the variant accumulates, FOXA2 and the like were found (Nat Genet 2020). We have shown that the GP2 variant can be a molecular mechanism for both type 2 diabetes and pancreatic cancer (Nat Commun 2020). When an Asian characteristic variant was expressed in pancreatic β-cells, GLP-1R altered insulin secretion (Nat Genet 2019) and PAX4 showed abnormal expression of endoplasmic reticulum calcium chaperone (HGV 2021). Genome editing was added to iPS cells, and functional analysis of variants in diabetic target cells was also performed (unpublished).
|
